<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">OXANDROLONE</span><br/>(ox-an'dro-lone)<br/><span class="topboxtradename">Oxandrin<br/></span><b>Classifications:</b> <span class="classification">hormones &amp; synthetic substitutes</span>; <span class="classification">androgen/anabolic steroid</span><br/><b>Prototype: </b>Testosterone<br/><b>Pregnancy Category: </b>X<br/><b>Controlled Substance: </b>Schedule III<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>2.5 mg tablets</p>
<h1><a name="action">Actions</a></h1>
<p>Synthetic steroid with anabolic and androgenic activity. Controls development and maintenance of secondary sexual characteristics.</p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p> <b>Androgenic activity:</b> Responsible for the growth spurt of the adolescent and for growth termination by epiphyseal closure. In males and some females
         reduces excretion of phosphorus, nitrogen, potassium, sodium, and chloride. Increases erythropoiesis, possibly by stimulating
         production of renal or extrarenal erythropoietin, and promotes vascularization and darkening of skin. Antagonizes effects
         of estrogen excess on female breast and endometrium. <b>Anabolic activity:</b> Increases protein metabolism and decreases its catabolism. Large doses suppress spermatogenesis, thereby causing testicular
         atrophy.
      </p>
<h1><a name="uses">Uses</a></h1>
<p>Adjunctive therapy to promote weight gain, offset protein catabolism associated with prolonged administration of corticosteroids,
         relieve bone pain accompanying osteoporosis.
      </p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Hypersensitivity or toxic reactions to androgens; severe cardiac, hepatic, or renal disease; pregnancy (category X), lactation;
         possibility of virilization of external genitalia of female fetus; polycythemia; hypercalcemia; known or suspected prostatic
         or breast cancer in males; benign prostatic hypertrophy with obstruction; patients easily stimulated sexually; older adults,
         asthenic males who may react adversely to androgenic overstimulation; conditions aggravated by fluid retention; hypertension.
      </p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Cardiac, hepatic, and mild to moderate renal disease, hypercholesterolemia, heart failure, peripheral edema, arteriosclerosis,
         coronary artery disease, MI; cholestasis; diabetes mellitus; prostatic hypertrophy; prepubertal males, geriatric patients,
         acute intermittent porphyria.
      </p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Weight Gain</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 2.5 mg b.i.d. to q.i.d. (max: 20 mg/d) for 24 wk<br/><span class="rdage">Child:</span> <span class="rdroute">PO</span> 0.10.25 mg/kg/d<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Oral</span><br/><ul>
<li>Individualize doses; great variations in response exist.</li>
<li>Store at 15°30° C (59°86° F).</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">CNS:</span> Habituation, excitation, insomnia, depression, changes in libido. <span class="typehead">Urogenital:</span> <span class="speceff-common">Males:</span> Phallic enlargement, increased frequency or persistence of erections, inhibition of testicular function, testicular atrophy,
      oligospermia, impotence, chronic priapism, epididymitis, bladder irritability; <span class="speceff-common">Females:</span> Clitoral enlargement, menstrual irregularities. <span class="typehead">Hepatic:</span> Cholestatic jaundice with or without <span class="speceff-life">hepatic necrosis and death, hepatocellular neoplasms, peliosis hepatitis (long-term use)</span>. <span class="typehead">Skin:</span> Hirsutism and male pattern baldness in females, acne. <span class="typehead">Endocrine:</span> Gynecomastia, deepening of voice in females, premature closure of epiphyses in children, edema, decreased glucose tolerance. 
      <h1><a name="dtintefer">Diagnostic Test Interference</a></h1>
<p>May decrease levels of thyroxine-binding globulin (decreased total T<sub>4</sub> and increased T<sub>3</sub> RU and free T<sub>4</sub>).
      </p>
<h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span> May increase INR with <b>warfarin.</b> May inhibit metabolism of <span class="classification">oral hypoglycemic agents</span>. Concomitant <span class="classification">steroids</span> may increase edema. <span class="typehead">Herbal:</span> <b>Echinacea</b> may increase risk of hepatotoxicity. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1>Not studied. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Monitor weight closely throughout therapy.</li>
<li>Assess for and report development of edema or S&amp;S of jaundice (see Appendix F).</li>
<li>Lab tests: Monitor periodically liver function, lipid profile, Hct and Hgb, PT and INR, serum electrolytes, and CPK.</li>
<li>Withhold and notify physician if hypercalcemia develops in breast cancer patient.</li>
<li>Monitor growth in children closely.</li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Women: Report signs of virilization, including acne and changes in menstrual periods.</li>
<li>Men: Report too frequent or prolonged erections or appearance/worsening of acne.</li>
<li>Report S&amp;S of jaundice (see Appendix F) or edema.</li>
<li>Monitor blood glucose for loss of glycemic control if diabetic.</li>
<li>Do not breast feed while taking this drug.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>